Literature DB >> 31858141

Impact of Baseline Characteristics on Future Episodes of Bloodstream Infections: Multistate Model in Septic Patients With Bloodstream Infections.

M Cristina Vazquez Guillamet1,2, Rodrigo Vazquez2, Jonas Noe3, Scott T Micek4, Victoria J Fraser5, Marin H Kollef2.   

Abstract

BACKGROUND: Looking only at the index infection, studies have described risk factors for infections caused by resistant bacteria. We hypothesized that septic patients with bloodstream infections may transition across states characterized by different microbiology and that their trajectory is not uniform. We also hypothesized that baseline risk factors may influence subsequent blood culture results.
METHODS: All adult septic patients with positive blood cultures over a 7-year period were included in the study. Baseline risk factors were recorded. We followed all survivors longitudinally and recorded subsequent blood culture results. We separated states into bacteremia caused by gram-positive cocci, susceptible gram-negative bacilli (sGNB), resistant GNB (rGNB), and Candida spp. Detrimental transitions were considered when transitioning to a culture with a higher mortality risk (rGNB and Candida spp.). A multistate Markov-like model was used to determine risk factors associated with detrimental transitions.
RESULTS: A total of 990 patients survived and experienced at least 1 transition, with a total of 4282 transitions. Inappropriate antibiotics, previous antibiotic exposure, and index bloodstream infection caused by either rGNB or Candida spp. were associated with detrimental transitions. Double antibiotic therapy (beta-lactam plus either an aminoglycoside or a fluoroquinolone) protected against detrimental transitions.
CONCLUSION: Baseline characteristics that include prescribed antibiotics can identify patients at risk for subsequent bloodstream infections caused by resistant bacteria. By altering the initial treatment, we could potentially influence future bacteremic states.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Markov model; bloodstream infections; combination therapy; sepsis; transitions

Year:  2020        PMID: 31858141      PMCID: PMC7947980          DOI: 10.1093/cid/ciz1206

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  35 in total

Review 1.  The rise and fall of antimicrobial resistance.

Authors:  M Lipsitch
Journal:  Trends Microbiol       Date:  2001-09       Impact factor: 17.079

2.  Impact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysis.

Authors:  Pilar Retamar; María M Portillo; María Dolores López-Prieto; Fernando Rodríguez-López; Marina de Cueto; María V García; María J Gómez; Alfonso Del Arco; Angel Muñoz; Antonio Sánchez-Porto; Manuel Torres-Tortosa; Andrés Martín-Aspas; Ascensión Arroyo; Carolina García-Figueras; Federico Acosta; Juan E Corzo; Laura León-Ruiz; Trinidad Escobar-Lara; Jesús Rodríguez-Baño
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

3.  Post-Acute Care Use and Hospital Readmission after Sepsis.

Authors:  Tiffanie K Jones; Barry D Fuchs; Dylan S Small; Scott D Halpern; Asaf Hanish; Craig A Umscheid; Charles A Baillie; Meeta Prasad Kerlin; David F Gaieski; Mark E Mikkelsen
Journal:  Ann Am Thorac Soc       Date:  2015-06

4.  Markov models in medical decision making: a practical guide.

Authors:  F A Sonnenberg; J R Beck
Journal:  Med Decis Making       Date:  1993 Oct-Dec       Impact factor: 2.583

5.  The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.

Authors:  Alan A Montgomery; Tom Fahey; Yoav Ben-Shlomo; James Harding
Journal:  J Hypertens       Date:  2003-09       Impact factor: 4.844

Review 6.  Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies.

Authors:  D N Fish; S C Piscitelli; L H Danziger
Journal:  Pharmacotherapy       Date:  1995 May-Jun       Impact factor: 4.705

7.  Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock.

Authors:  Cristina Vazquez-Guillamet; Michael Scolari; Marya D Zilberberg; Andrew F Shorr; Scott T Micek; Marin Kollef
Journal:  Crit Care Med       Date:  2014-11       Impact factor: 7.598

8.  Metagenomic Analysis Reveals Dynamic Changes of Whole Gut Microbiota in the Acute Phase of Intensive Care Unit Patients.

Authors:  Masahiro Ojima; Daisuke Motooka; Kentaro Shimizu; Kazuyoshi Gotoh; Ayumi Shintani; Kazuhisa Yoshiya; Shota Nakamura; Hiroshi Ogura; Tetsuya Iida; Takeshi Shimazu
Journal:  Dig Dis Sci       Date:  2015-12-29       Impact factor: 3.199

9.  Population-Based Active Surveillance for Culture-Confirmed Candidemia - Four Sites, United States, 2012-2016.

Authors:  Mitsuru Toda; Sabrina R Williams; Elizabeth L Berkow; Monica M Farley; Lee H Harrison; Lindsay Bonner; Kaytlynn M Marceaux; Rosemary Hollick; Alexia Y Zhang; William Schaffner; Shawn R Lockhart; Brendan R Jackson; Snigdha Vallabhaneni
Journal:  MMWR Surveill Summ       Date:  2019-09-27

10.  Predicting Resistance to Piperacillin-Tazobactam, Cefepime and Meropenem in Septic Patients With Bloodstream Infection Due to Gram-Negative Bacteria.

Authors:  M Cristina Vazquez-Guillamet; Rodrigo Vazquez; Scott T Micek; Marin H Kollef
Journal:  Clin Infect Dis       Date:  2017-10-30       Impact factor: 9.079

View more
  1 in total

1.  Cefiderocol-Based Combination Therapy for "Difficult-to-Treat" Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives.

Authors:  Davide Fiore Bavaro; Alessandra Belati; Lucia Diella; Monica Stufano; Federica Romanelli; Luca Scalone; Stefania Stolfa; Luigi Ronga; Leonarda Maurmo; Maria Dell'Aera; Adriana Mosca; Lidia Dalfino; Salvatore Grasso; Annalisa Saracino
Journal:  Antibiotics (Basel)       Date:  2021-05-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.